Pulse Biosciences (PLSE) Gross Margin (2021 - 2026)

Pulse Biosciences (PLSE) posted quarterly Gross Margin of 224.42% for Q3 2025, up 44.88% quarter-over-quarter from 407.17% in Q2 2022.

Pulse Biosciences (PLSE) Gross Margin (2021 - 2026) Analysis & Trends

Pulse Biosciences' Gross Margin history runs 3 years deep, the most recent figure standing at 224.42% for Q3 2025.

In Q3 2025, Gross Margin changed N/A year-over-year to 224.42%; the TTM figure through Sep 2025 stood at 224.42% (changed N/A YoY), while the FY2022 annual figure was 1606.29%, down 156571.0% from the prior year.
Gross Margin for Q3 2025 stood at 224.42%, up from 407.17% in the prior quarter.
The five-year high for Gross Margin was 26.66% in Q3 2021, with the low at 407.17% in Q2 2022.
The 3-year median for Gross Margin is 104.73% (2022), against an average of 162.64%.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Intuitive Surgical	132.71 Bn	127.50 Bn	1.96 Bn	67.78%
2	Becton Dickinson	51.57 Bn	50.71 Bn	2.32 Bn	46.46%
3	Alcon	35.52 Bn	34.17 Bn	1.68 Bn	59.33%
4	Resmed	33.28 Bn	31.81 Bn	861.22 Mn	58.84%
5	Medline	27.86 Bn	25.18 Bn	2.22 Bn	28.82%
6	West Pharmaceutical Services	25.15 Bn	24.71 Bn	329.20 Mn	37.74%
7	Solventum	15.31 Bn	14.91 Bn	1.29 Bn	58.22%
8	Cooper Companies	14.86 Bn	14.72 Bn	735.40 Mn	68.00%
9	Baxter International	13.63 Bn	11.48 Bn	1.03 Bn	34.86%
10	Pulse Biosciences	3.33 Bn	3.33 Bn	161,000.00	37.10%

Download Data